Csl

CSL, an Australian Pharmaceutical Preparation Manufacturing company, reported its Scope 1 emissions as approximately 135,000,000 kg CO2e and Scope 2 emissions as approximately 151,000,000 kg CO2e in 2025.

The company has set several climate commitments. CSL aims to achieve a 40% absolute reduction in Scope 1 and 2 emissions by 2030, using the average annual emissions from fiscal years 2019–2021 as a baseline. Additionally, CSL has committed to Science Based Targets initiative (SBTi) near-term targets. Specifically, CSL Ltd. commits to reducing absolute Scope 1 GHG emissions by 42% by FY2030 from a FY2021 base year, and absolute Scope 2 GHG emissions by 42% by FY2030 from a FY2021 base year. These targets are considered consistent with reductions required to keep warming to 1.5°C. CSL Ltd. also commits that 73.1% of its suppliers by emissions covering purchased goods and services, capital goods, upstream transportation and distribution, business travel, and downstream transportation and distribution will have science-based targets by FY2030.